Media stories about Natus Medical (NASDAQ:BABY) have trended somewhat positive on Wednesday, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Natus Medical earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 46.8371498091993 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Natus Medical (BABY) traded up $0.15 during trading hours on Wednesday, hitting $32.95. The company’s stock had a trading volume of 271,877 shares, compared to its average volume of 393,219. Natus Medical has a 12 month low of $28.00 and a 12 month high of $43.60. The company has a quick ratio of 2.54, a current ratio of 3.32 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $1,090.00, a PE ratio of 3,295.00 and a beta of 0.54.
Natus Medical (NASDAQ:BABY) last issued its quarterly earnings results on Wednesday, February 7th. The medical equipment provider reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.54 by ($0.12). Natus Medical had a negative net margin of 4.05% and a positive return on equity of 11.36%. The firm had revenue of $131.40 million for the quarter, compared to the consensus estimate of $131.38 million. During the same quarter in the prior year, the firm earned $0.51 earnings per share. The company’s revenue was up 22.0% on a year-over-year basis. equities analysts forecast that Natus Medical will post 1.63 earnings per share for the current fiscal year.
BABY has been the topic of several research analyst reports. BidaskClub upgraded Natus Medical from a “strong sell” rating to a “sell” rating in a research report on Tuesday, March 6th. Roth Capital set a $39.00 target price on Natus Medical and gave the stock a “buy” rating in a report on Tuesday, February 27th. Zacks Investment Research cut Natus Medical from a “buy” rating to a “hold” rating in a report on Tuesday, December 26th. William Blair downgraded Natus Medical from an “outperform” rating to a “market perform” rating in a report on Monday, January 8th. Finally, Benchmark reiterated a “buy” rating and set a $49.00 price target (down previously from $55.00) on shares of Natus Medical in a report on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $44.33.
In other news, Director Ken Ludlum sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $31.68, for a total value of $126,720.00. Following the transaction, the director now directly owns 93,825 shares of the company’s stock, valued at approximately $2,972,376. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.50% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: “Natus Medical (BABY) Receiving Somewhat Favorable Press Coverage, Study Shows” was originally reported by BBNS and is owned by of BBNS. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://baseballnewssource.com/2018/03/14/natus-medical-baby-receives-daily-media-impact-rating-of-0-11/1972180.html.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.